# Aptevo Therapeutics Inc.: overview APVO · Nasdaq · CIK 1671584 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/apvo.md) · [Financials](/companies/apvo/financials.md) · [Filings](/companies/apvo/filings.md) · [Insiders](/companies/apvo/insiders.md) Latest reported revenue: [$0](/filings/0000950170-24-025428.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Mar 5, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000950170-24-025428). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(357.86)](/filings/0001193125-25-269598.md) | not reported | [(1581.81)](/filings/0001193125-26-221661.md) | [(151.29)](/filings/0001193125-26-350559.md) | [(2.23)](/filings/0001193125-25-269598.md) | not reported | [(6.41)](/filings/0001193125-26-221661.md) | [(5.31)](/filings/0001193125-26-350559.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.3](/filings/0000950170-23-010757.md) | [3.1](/filings/0000950170-24-025428.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(174.1%)](/filings/0000950170-23-010757.md) | [(919.7%)](/filings/0000950170-24-025428.md) | not reported | not reported | not reported | | Net margin | % | [(231.5%)](/filings/0000950170-23-010757.md) | [257.8%](/filings/0000950170-24-025428.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(6.07)](/filings/0000950170-23-010757.md) | [1.57](/filings/0000950170-24-025428.md) | [(2316.83)](/filings/0000950170-25-020467.md) | [(31460.23)](/filings/0001193125-26-126278.md) | [(87.27)](/filings/0001193125-26-126278.md) | | Free cash flow | $m | [(22.4)](/filings/0000950170-23-010757.md) | [(21.1)](/filings/0000950170-24-025428.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/apvo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $56.4k | 12,713 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $48.0k | 10,821 | | Reduced −2,516 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $18.4k | 4,142 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $3.2k | 730 | | Reduced −2,715 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $1.6k | 360 | | Unchanged | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $484 | 109 | | Unchanged | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $138 | 31 | | New +31 | | [GSA CAPITAL PARTNERS LLP](/funds/1362033.md) | 2026-06-30 | $96 | 21,539 | | Added +1,901 | | [CWM, LLC](/funds/1535847.md) | 2026-03-31 | $21 | 5 | | Not compared | | [DANSKE BANK A/S](/funds/800177.md) | 2026-06-30 | $4 | 1 | | Unchanged | ## Recent filings [All 734 filings](/companies/apvo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 08:13 ET | [8-K](/filings/0001193125-26-431079.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-431079 | | 2026-10-23 | 16:05 ET | [8-K](/filings/0001193125-26-430419.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001193125-26-430419 | | 2026-10-14 | 08:52 ET | [8-K](/filings/0001193125-26-421076.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-421076 | | 2026-09-24 | 08:10 ET | [8-K](/filings/0001193125-26-400213.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-400213 | | 2026-09-23 | 16:43 ET | [8-K](/filings/0001193125-26-399545.md) | 5.07 Shareholder vote results | 0001193125-26-399545 | | 2026-09-03 | 08:15 ET | [8-K](/filings/0001193125-26-381098.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-381098 | | 2026-08-31 | 17:29 ET | [DEF 14A](/filings/0001193125-26-376763.md) | Proxy statement, period 2026-09-22 | 0001193125-26-376763 | | 2026-08-21 | 16:10 ET | [S-1](/filings/0001193125-26-361103.md) | Registration statement | 0001193125-26-361103 | | 2026-08-21 | 16:05 ET | [8-K](/filings/0001193125-26-361079.md) | 5.07 Shareholder vote results | 0001193125-26-361079 | | 2026-08-14 | 08:15 ET | [10-Q](/filings/0001193125-26-350559.md) | Quarterly report, period 2026-06-30 | 0001193125-26-350559 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-126278.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1671584 - Tickers: APVO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:45 ET. No prices; not investment advice.